While an increasing number of options are available or in development for effectively treating patients with HCV infection, many clinicians find it challenging to keep abreast of important developments in HCV therapeutics. To address this problem, this CME dinner program series will use case studies to highlight and discuss the relative merits and clinical significance of new findings in HCV medicine presented at the 49th Annual Meeting of the European Association for the Study of the Liver (49th EASL).
Because the focus of the dinner programs will be on case studies, participants will need to be familiar with data from the 49th EASL that may be applied and discussed. Therefore, prior to attending a dinner program, participants will view an Internet presentation that summarizes and discusses the key data presented at the 49th EASL. As a result of this blended learning approach, participants will not only gain an increased understanding of key data presented at the 49th EASL, they will also be better prepared to address their HCV patients' health needs and provide optimal care, which should improve adherence, increase individualized care, reduce adverse effects and drug-drug interactions, and improve quality of life.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc.. It is not a session created by or presented at the 49th EASL and it is not sanctioned by the 49th EASL.
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection.
After completing this activity, the participant should be better able to:
Employ current treatment protocols for CHC in clinical practice, including the studies and data presented at the 49th EASL,
to improve patient care
| Tuesday, April 22, 2014 Los Angeles, CA |
Thursday, May 1, 2014 Miami, FL |
| Tuesday, April 29, 2014 Chicago, IL |
Tuesday, May 6, 2014 Boston, MA |
| Tuesday, April 29, 2014 San Francisco, CA |
Tuesday, May 6, 2014 New York, NY |
| Thursday, May 1, 2014 Baltimore, MD |
Tuesday, May 13, 2014 Houston, TX |
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
|
Nezam H. Afdhal, MD |
Fred Poordad, MD |
|
Maurizio Bonacini, MD Director, HIV-Liver Clinic Department of Transplantation California Pacific Medical Center San Francisco, California |
Sammy Saab, MD Professor of Medicine and Surgery The Pfleger Liver Institute David Geffen School of Medicine University of California, Los Angeles Los Angeles, California |
|
Lennox Jeffers, MD |
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exceptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then provide that information to the supporting pharmaceutical companies to the best of our ability.
Supported by an unrestricted educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
